Inspiration and recipes in ‘Our American Dream Cookbook'
Advertisement
The book wraps up with a nod to its roots — beer — offering a five-step guide to evaluating a brew. You might see the book as a tribute to Jim Koch's vision of combining business success (he began brewing Samuel Adams beer over 40 years ago) with social impact, but it's also a good read, especially for anyone dreaming of starting their own venture. $30. Available at
Get Winter Soup Club
[Coming Soon] A six-week series featuring soup recipes and cozy vibes, plus side dishes and toppings, to get us all through the winter.
Enter Email
Sign Up
Ann Trieger Kurland can be reached at
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Novanta to Present at Baird 2025 Global Healthcare Conference on Tuesday, September 9, 2025
BOSTON, August 12, 2025--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Matthijs Glastra, Chair & Chief Executive Officer, and Robert Buckley, Chief Financial Officer, is scheduled to present at Baird 2025 Global Healthcare Conference on Tuesday, September 9, 2025, in New York, NY. About Novanta Novanta is a leading global supplier of core technology solutions that give medical, life science, and advanced industrial original equipment manufacturers a competitive advantage. We combine deep proprietary expertise and competencies in precision medicine, precision manufacturing, robotics and automation, and advanced surgery with a proven ability to solve complex technical challenges. This enables Novanta to engineer proprietary technology solutions that deliver extreme precision and performance, tailored to our customers' demanding applications. The driving force behind our growth is the team of innovative professionals who share a commitment to innovation, the Novanta Growth System, and our customers' success. Novanta's common shares are quoted on Nasdaq under the ticker symbol "NOVT." More information about Novanta is available on the Company's website at For additional information, please contact Novanta Inc. Investor Relations at (781) 266-5137 or InvestorRelations@ View source version on Contacts Novanta Inc. Investor Relations Contact:Ray Nash(781) 266-5137 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
Compass Therapeutics Announces Proposed Public Offering
BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. ('Compass') (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the launch of an underwritten public offering of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Compass. Compass also intends to grant the underwriters a 30-day option to purchase additional shares of its common stock offered in the public offering under the same terms and conditions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Compass intends to use the net proceeds from the offering to conduct initial preparations for commercial readiness, to fund research and clinical development of its product candidates, and for general corporate purposes. Jefferies, Piper Sandler and Guggenheim Securities are acting as joint active bookrunning managers for the offering. A shelf registration statement on Form S-3 relating to the securities offered in the public offering described above was filed with the Securities and Exchange Commission (the 'SEC') on August 30, 2024 and declared effective by the SEC on September 6, 2024. The offering will be made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at Copies of the preliminary prospectus supplement and the accompanying prospectus, when available, may also be obtained by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@ Piper Sandler & Co. by mail at 350 North 5th Street, Suite 1000, Minneapolis, Minnesota 55401 or by email at prospectus@ and Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, telephone: (212) 518-9544, email: GSEquityProspectusDelivery@ This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Compass Therapeutics Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass has built a robust pipeline of novel product candidates designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. The company plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The Company was founded in 2014 and is headquartered in Boston, Massachusetts. Forward-Looking Statements Various statements in this release concerning the timing, size, structure and completion of the proposed public offering on the anticipated terms or at all may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of substantial risks and uncertainties, many of which are outside Compass's control, that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include fluctuations in Compass's stock price, changes in market conditions, the final terms of the public offering and satisfaction of customary closing conditions related to the public offering, as well as those risks more fully discussed in the section entitled 'Risk Factors' in the prospectus supplement and registration statement referenced above and in Compass's Annual Report on Form 10-K for the year ended December 31, 2024, filed on February 27, 2025, and subsequent reports with the SEC. There can be no assurance that Compass will be able to complete the public offering on the anticipated terms. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Compass undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law. Investor Contactir@ ContactAnna Gifford, Chief of Staffmedia@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
GOGO Charters Expands with New England Intercity Bus Service
-- Boston to Serve as Regional Hub for 2026 Launch -- -- Daily Routes Connecting Major New England Cities Starting at $10 -- BOSTON, Aug. 12, 2025 /PRNewswire/ -- GOGO Charters is expanding into New England with new daily routes set to launch in 2026. The expanded service will connect eight cities, including Boston, Hartford, New Haven, Providence and Manchester and more, offering travelers new ways to move easily and affordably across the region. This rollout introduces three new daily routes connecting major metro areas with nearby cities, communities, and college towns. It marks the next phase of GOGO Charters' regional expansion, following the company's January launch and growing interest sparked by earlier announcements in key markets nationwide. The cities included in this next phase of service are: Boston, MA; Hartford, CT; Lowell, MA; Manchester, NH; New Haven, CT; Norwich, CT; Providence, RI; Worcester, MA. This expansion is part of GOGO Charters' larger vision to build a connected, nationwide network of reliable ground transportation. By offering frequent service along high-demand corridors, GOGO Charters is helping redefine how people experience intercity and regional travel. Route Details & Transfer Locations: Boston, MA <> Manchester, NH Boston, MA: Boston Marriott Long Wharf (296 State St Boston, MA 02109) Lowell, MA: UMass Lowell Campus Recreation Center (322 Aiken St Lowell, MA 01854) Manchester, NH: DoubleTree by Hilton Manchester Downtown (700 Elm St Manchester, NH 03101) Boston, MA <> New Haven, CT (via Hartford, CT) Boston, MA: Boston Marriott Long Wharf (296 State St Boston, MA 02109) Worcester, MA: AC Hotel Worcester (125 Front St Worcester, MA 01608) Hartford, CT: Hartford Marriott Downtown (200 Columbus Blvd Hartford, CT 06103) New Haven, CT: Graduate by Hilton New Haven (1151 Chapel St New Haven, CT 06511) Boston, MA <> New Haven, CT (via Providence, RI) Boston, MA: Boston Marriott Long Wharf (296 State St Boston, MA 02109) Providence, RI: Graduate by Hilton Providence (11 Dorrance St Providence, RI 02903) Norwich, CT: Mohegan Sun (1 Mohegan Sun Blvd Uncasville, CT 06382) New Haven, CT: Graduate by Hilton New Haven (1151 Chapel St New Haven, CT 06511) * Service to begin in 2026; Routes subject to change Fares will start at just $10 and will vary based on distance and demand. For more details about routes, stops and service updates, visit our Boston city page. Passengers can expect a comfortable ride aboard luxury motorcoaches featuring spacious seating, onboard WiFi, and climate control. The GOGO Charters mobile app streamlines the booking experience with digital tickets and real-time bus tracking. With flexible pricing, daily departures, and a commitment to comfort and sustainability, GOGO Charters offers a smarter, more convenient option for regional travel. More routes are set to launch throughout 2026 as GOGO Charters continues to build a national network of charter bus connections. Visit us at and follow our journey @GOGOCharters. About GOGO Charters: GOGO Charters is a leading provider of luxury charter bus and minibus transportation services, connecting cities and communities across the U.S. through upscale, reliable, and environmentally friendly travel solutions. From corporate and educational trips, to leisure travel and intercity routes, GOGO Charters is committed to delivering high-quality, luxury experiences that strengthen regional ties and support economic growth. For more information, visit or download the new GOGO Charters app from the Apple App Store or Google Play Store. Media Contacts:Jon@ Media@ Press Kit View original content to download multimedia: SOURCE GOGO Charters Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
